Researchers looked specifically at head-to-head randomized clinical trials of next-in-class cancer drugs against existing agents in the same class. Less than one-quarter of next-in-class cancer drugs ...
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, ...
WEST LAFAYETTE – Purdue University researcher Andrea Kasinski is developing a new class of cancer drugs using microRNAs, ...
Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
Pharmaceutical Technology on MSN
Corcept’s first-in-class ovarian cancer drug gains FDA approval
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and ...
Telmisartan, an FDA-approved blood pressure drug, could boost a certain cancer treatment's effectiveness against tumors, a ...
In 22.2% of trials, there was a survival benefit with the next-in-class agent. Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results